Add like
Add dislike
Add to saved papers

Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.

Oncology Letters 2018 September
The present study aimed to identify the probable anti-Condyloma acuminata (CA) mechanism of microRNA-375 (miRNA-375) in human papillomavirus (HPV). Firstly, the overexpression of miRNA-375 significantly suppressed cell proliferation, increased lactate dehydrogenase activity and induced apoptosis in HPV-18(+) cervical cancer cells. The overexpression of miRNA-375 significantly increased caspase-3 and caspase-9 activities, induced B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein, tumor protein 53 and cyclin-dependent kinase inhibitor 1 protein expression and suppressed cyclin D1 and survivin protein expression in HPV-18(+) cervical cancer cells. The overexpression of miRNA-375 significantly suppressed the levels of protein expression of ubiquitin-protein ligase E3A (UBE3A) and Insulin-like growth factor-1 receptor (IGF-1R) in HPV-18(+) cervical cancer cells. To conclude, it was identified that the probable anti-CA mechanism of miRNA-375 modulates HPV through the UBE3A and IGF-1R pathway in cervical cancer cells.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app